Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.2852W HIGH $20.22
Volume
92.39 K
Value Traded
18.39 M
Short % Float
11.71%
-7.8%Week
-22.93%1 Month
-28.11%3 Month
-2.77%6 Month
+566.54%5 Year
+48.74%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.80 B
EPS (TTM)
-0.36
P/E Ratio
-
Ent. Value
1.51 B
Total Shares
142.48 M
Float Shares
103.05 M
Insiders
27.67%
Institutions
79.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TRVI Catalyst Timeline
Dated clinical, regulatory and corporate events for Trevi Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Trevi Therapeutics, Inc.
348Total events
4Upcoming
55Tier-1 (high impact)
2019 to 2030Coverage
Upcoming catalysts 2
Event history 50
●Type B MeetingHaduvio (nalbuphine ER)FDA Meeting
FDA meeting request submitted to discuss non-IPF ILD development plan
non-IPF ILD-related chronic coughsource ↗
▲Trial InitiationHaduvio (nalbuphine ER)Trial
Expected initiation of Phase 3 OCEAN-2 trial
idiopathic pulmonary fibrosis-related chronic coughsource ↗
◆Poster PresentationHaduvio (nalbuphine ER)Presentation
Poster on effect of nalbuphine ER on breathlessness in IPF patients from CORAL trial at ATS 2026
IPF-related chronic coughsource ↗
◆Oral PresentationHaduvio (nalbuphine ER)Presentation
Data Highlights from Trevi's ATS 2026 Presentations
chronic cough in IPF, non-IPF ILD, and RCCsource ↗
◆Oral PresentationHaduvio (nalbuphine ER)Presentation
Oral presentation of primary and subgroup analyses from Phase 2b CORAL trial of nalbuphine ER for IPF-related chronic cough at ATS 2026
IPF-related chronic coughsource ↗
◆Poster PresentationHaduvio (nalbuphine ER)Presentation
Poster on nalbuphine ER reducing cough bouts in RCC patients from RIVER trial at ATS 2026
refractory chronic coughsource ↗
◆Poster PresentationPresentation
Poster on burden of chronic cough in ILD patients from US survey at ATS 2026
interstitial lung diseasesource ↗
◆Poster PresentationHaduvio (nalbuphine ER)Presentation
Poster on pharmacokinetics and safety of nalbuphine ER co-administered with pirfenidone or nintedanib at ATS 2026
IPF-related chronic coughsource ↗
◆Oral PresentationHaduvio (nalbuphine ER)Presentation
Corporate Presentation at Bank of America Global Healthcare Conference 2026
chronic cough in IPF, non-IPF ILD, and RCCsource ↗
◆R&D DayHaduvio (nalbuphine ER)Presentation
Trevi Therapeutics Investor and Analyst Day
chronic cough in IPF, non-IPF ILD, and RCCsource ↗
▼Equity OfferingCorporate
Closing of $173 million underwritten public offering of common stock
▼Equity OfferingCorporate
Pricing of $150 million underwritten public offering of common stock
◆Oral PresentationPresentation
25th Annual Needham Virtual Healthcare Conference Fireside Chat
◆Trial InitiationHaduvio (nalbuphine ER)Trial
First Phase 3 pivotal trial initiation on track for Q2 2026
idiopathic pulmonary fibrosis-related chronic coughsource ↗
▲Trial InitiationHaduvio (nalbuphine ER)Trial
Initiated Phase 3 OCEAN-1 trial
idiopathic pulmonary fibrosis-related chronic coughsource ↗
◆Oral PresentationPresentation
Access USA, Rare Disease Summit 2026 Panel: Architecting Success – Building a Foundation for Rare Disease Launch Excellence
◆Quarterly UpdateCorporate
Q4 and Year End 2025 Financial Results and Business Update Conference Call
▲End Of Phase 2 MeetingHaduvio (nalbuphine ER)FDA Meeting
End-of-Phase 2 meeting with FDA; gained alignment on Phase 3 program for IPF-related chronic cough
idiopathic pulmonary fibrosis-related chronic coughsource ↗
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference Fireside Chat
▲End Of Phase 2 MeetingHaduvio (nalbuphine ER)FDA Meeting
End-of-Phase 2 meeting with FDA completed, alignment gained for development program
idiopathic pulmonary fibrosis-related chronic coughsource ↗
◆Oral PresentationHaduvio (nalbuphine ER)Presentation
Fireside chat at Oppenheimer 36th Annual Healthcare Life Sciences Conference
chronic cough in IPF, non-IPF ILD, RCCsource ↗
▲PublicationHaduvio (nalbuphine ER)Presentation
Publication of Phase 2b CORAL trial results in JAMA
chronic cough in patients with idiopathic pulmonary fibrosis (IPF)source ↗
◆Oral PresentationPresentation
Participation in 15th Annual LifeSci Partners Corporate Access Event
◆Management ChangeCorporate
David Hastings appointed as Chief Financial Officer effective January 6, 2026
◆End Of Phase 2 MeetingHaduvio (nalbuphine ER)FDA Meeting
FDA End-of-Phase 2 meeting for Haduvio in IPF chronic cough
chronic cough in patients with idiopathic pulmonary fibrosissource ↗
▲PublicationHaduvio (nalbuphine ER)Presentation
Phase 2b CORAL trial results published in JAMA
idiopathic pulmonary fibrosis-related chronic coughsource ↗
◆Oral PresentationHaduvio (nalbuphine ER)Presentation
Fireside chat at Stifel 2025 Healthcare Conference
chronic cough in IPF, non-IPF ILD, RCCsource ↗
◆Oral PresentationHaduvio (nalbuphine ER)Presentation
Oral presentation of key efficacy and safety results from Phase 2b CORAL trial of nalbuphine ER for chronic cough in IPF at CHEST 2025
chronic cough in patients with idiopathic pulmonary fibrosis (IPF)source ↗
◆Poster PresentationHaduvio (nalbuphine ER)Presentation
Poster presentation of patient-reported outcomes from Phase 2a RIVER trial of nalbuphine ER for RCC at CHEST 2025
refractory chronic cough (RCC)source ↗
◆End Of Phase 2 MeetingHaduvio (nalbuphine ER)FDA Meeting
End-of-Phase 2 meeting request submission to FDA for IPF chronic cough program
chronic cough in idiopathic pulmonary fibrosissource ↗
◆Poster PresentationHaduvio (nalbuphine ER)Presentation
Poster presentation of efficacy and safety results from Phase 2a RIVER trial at ERS 2025
refractory chronic coughsource ↗
◆Poster PresentationHaduvio (nalbuphine ER)Presentation
Poster presentation of responder analysis from Phase 2a RIVER trial at ERS 2025
refractory chronic coughsource ↗
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
H.C. Wainwright & Co. 27th Annual Global Investment Conference
▲Full ResultsHaduvio (nalbuphine ER)Clinical Data
Full data set from CORAL trial received
chronic cough in patients with IPFsource ↗
Past FDA Catalysts and PDUFA Decisions
How TRVI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-07 | Nalbuphine ER (Haduvio) | Phase 2a data presentation | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$135M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 35%
Micro Cap(rank 231 of 658)
Percentile Rank
Trevi Therapeutics, Inc. carries a moderate pipeline score (42/100), with $337M risk-adjusted pipeline value, led by Haduvio (nalbuphine ER) in Hepatic Impairment (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Haduvio (nalbuphine ER) Small moleculeNCT07036029 | Idiopathic Pulmonary Fibrosis | Phase 3 | COMPLETED | 522 | Jun 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every TRVI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Haduvio | chronic cough associated with idiopathic pulmonary fibrosis and other conditions | 2026-07-30 | statistically-significant reduction in cough frequency, consistent across baseline cough frequencies and showed improvements in patient-reported outcomesRead More | Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Heffernan Michael ThomasDirector | Option | 18,421 24,772 held | $3.04 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TRVI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 15.5 % (72.2 %) | 246.59 M | 13.22 M |
TRVI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRVI ranks across every disease it competes in
Competitive Position is a premium feature
See how TRVI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRVI News
TRVITrevi Therapeutics to Participate in Upcoming September Conferences
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will participate in several upcoming conferences in September 2026. Key representatives will engage in fireside chats and panel discussions to discuss their investigational therapy Haduvio for chronic cough associated with idiopathic pulmonary fibrosis and other conditions. Haduvio has shown significant efficacy in clinical trials, addressing a critical unmet need.
Read more →TRVITrevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Trevi Therapeutics announced the acceptance of two abstracts for the European Respiratory Society Congress 2026. Professor Marlies Wijsenbeek will present findings from the Phase 2b CORAL trial on nalbuphine ER for chronic cough in IPF patients. Dr. Imran Satia will present data from the Phase 2a RIVER trial on the same treatment for refractory chronic cough.
Read more →TRVITrevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics reported its Q2 2026 financial results and announced the initiation of the Phase 3 OCEAN-1 trial for patients with IPF-related chronic cough. The company also began the Phase 2b LAKE trial for refractory chronic cough and plans to initiate the OCEAN-2 trial in Q3 2026. Despite a net loss of $17.8 million, Trevi maintains a strong cash position to support its clinical development efforts.
Read more →TRVITrevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Trevi Therapeutics will host a conference call on August 6, 2026, to discuss its financial results for Q2 2026 and provide a corporate update. The company is focused on its investigational therapy Haduvio for chronic cough associated with idiopathic pulmonary fibrosis and other conditions. Haduvio has demonstrated significant efficacy in clinical trials, addressing a critical need in the market.
Read more →TRVITrevi Therapeutics to Participate in Upcoming August Conferences
Trevi Therapeutics, Inc. will participate in two upcoming conferences in August 2026, highlighting its investigational therapy Haduvio for chronic cough. The company aims to address the high unmet need in patients with idiopathic pulmonary fibrosis and refractory chronic cough. Haduvio has shown promising results in clinical trials, demonstrating significant reductions in cough frequency.
Read more →TRVI▲ +6.3%on this news
Trevi Therapeutics Announces Upcoming June and July Event Schedule
Trevi Therapeutics has announced its participation in several key events in June and July 2026, including the BIO International Convention and the ERS Cough Conference. The company is focused on advancing its investigational therapy, Haduvio, for chronic cough associated with idiopathic pulmonary fibrosis and other conditions. Haduvio has shown statistically significant results in reducing cough frequency in clinical trials.
Read more →TRVITrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics reported its Q1 2026 financial results, highlighting a successful stock offering that raised approximately $162 million. This funding extends the company's cash runway into 2030, allowing for the advancement of its lead therapy, Haduvio, for chronic cough indications. The company plans to initiate multiple clinical trials this quarter, including a Phase 3 trial for IPF-related chronic cough.
Read more →TRVITrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Trevi Therapeutics has announced that it will deliver an oral presentation and present several posters at the ATS 2026 International Conference. This includes results from the Phase 2b CORAL trial evaluating nalbuphine ER for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The presentations will cover various analyses, indicating significant efficacy in reducing cough frequency for patients with chronic cough. This highlights the potential impact nalbuphine ER may have on the treatment landscape for patients suffering from chronic coughs associated with IPF and other conditions.
Read more →TRVITrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
Trevi Therapeutics will host a conference call on May 5, 2026, to discuss its financial results for Q1 2026 and provide a corporate update. The company is focused on its investigational therapy Haduvio for chronic cough associated with idiopathic pulmonary fibrosis and other conditions. Haduvio has demonstrated significant efficacy in clinical trials, targeting a high unmet medical need.
Read more →TRVITrevi Therapeutics to Participate in Upcoming May Events
Trevi Therapeutics will participate in several key events in May 2026, including an Investor and Analyst Day and the Bank of America Global Healthcare Conference. The company aims to highlight its investigational therapy Haduvio, which targets chronic cough in patients with idiopathic pulmonary fibrosis and other conditions. These events will feature senior management and key opinion leaders in the field.
Read more →TRVI▼ -5.1%on this newsshared move
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Trevi Therapeutics has successfully closed a public offering, raising approximately $173 million by selling 13,340,000 shares at $13.00 each. This includes additional shares purchased by underwriters, reflecting strong market interest. The funds will be used to advance the development of Haduvio, an investigational therapy for chronic cough associated with various lung diseases.
Read more →TRVITrevi Therapeutics Announces Proposed Public Offering of Common Stock
Trevi Therapeutics has announced a proposed public offering of $150 million in common stock to support its investigational therapy Haduvio for chronic cough. The offering includes an option for underwriters to purchase an additional $22.5 million in shares. The company is working under a shelf registration statement filed with the SEC, and the final offering terms will be disclosed later.
Read more →TRVITrevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Trevi Therapeutics has announced the pricing of its underwritten public offering, raising approximately $150 million by selling 11.6 million shares at $13.00 each. The offering is expected to close around April 20, 2026, pending customary conditions. The company is developing Haduvio, an investigational therapy for chronic cough, which has shown significant efficacy in trials.
Read more →TRVITrevi Therapeutics to Participate in Upcoming Events
Trevi Therapeutics, Inc. has announced its participation in several upcoming healthcare events, including the Needham Virtual Healthcare Conference and the Raymond James Biotech Innovation Symposium. Senior management, including President and CEO Jennifer Good, will represent the company during these events. Trevi's investigational therapy Haduvio is designed for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and other cough-related conditions, addressing a significant unmet medical need in these populations. The company will also host an Investor and Analyst Day to further discuss their developments.
Read more →TRVITrevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Trevi Therapeutics has announced its fourth quarter and full year financial results for 2025, highlighting alignment with the FDA on its Phase 3 program for treating chronic cough associated with idiopathic pulmonary fibrosis. The company plans to initiate pivotal Phase 3 trials in 2026, supported by promising Phase 2 data. Trevi ended the year with $188.3 million in cash, ensuring sufficient funds for ongoing and future clinical trials. With an escalating need for effective treatments for chronic cough, Trevi aims to address gaps in therapies for this condition.
Read more →TRVITrevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
Trevi Therapeutics, Inc. will report its fourth quarter and year-end 2025 financial results on March 17, 2026. The conference call and webcast will provide business updates and review the company's progress. Trevi is developing Haduvio™, which has shown promise in clinical trials for treating chronic cough, particularly in patients with idiopathic pulmonary fibrosis and refractory chronic cough. The therapy, which targets a significant unmet medical need, is not currently scheduled by the U.S. DEA.
Read more →TRVI▼ -12%on this newsshared move
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
Trevi Therapeutics has successfully completed its End-of-Phase 2 meeting with the FDA, receiving guidance for its development program for Haduvio, an investigational therapy targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The company plans to conduct two pivotal Phase 3 trials, with the first trial expected to start in Q2 2026. This marks a significant step forward in addressing the unmet medical need for patients suffering from chronic cough related to IPF.
Read more →About Trevi Therapeutics, Inc.
Headquarters195 CHURCH STREET, NEW HAVEN, CT, 06510
BIOPHARMAWATCH ELITE PLUS
Trade the next TRVI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime